Stock MODTX MODUS THERAPEUTICS HOLDING AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Modus Therapeutics Holding AB

Equities

MODTX

SE0015987904

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:19:49 2024-04-26 am EDT 		5-day change 1st Jan Change
0.968 SEK -2.81% Intraday chart for Modus Therapeutics Holding AB -5.56% -44.21%
Feb. 21 Modus Therapeutics Holding AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
2023 Modus Therapeutics to Launch SEK40 Million Rights Offering, Issue Shares to Offset SEK20 Million Loan MT

Valuation

Fiscal Period: December 2021 2023 2024 2025 2026
Capitalization 1 61.18 62.35 34.79 - -
Enterprise Value (EV) 1 61.18 62.35 21.79 -12.21 33.79
P/E ratio - -1.72 x -1.29 x -0.93 x -0.77 x
Yield - - - - -
Capitalization / Revenue - - - - -
EV / Revenue - - - - -
EV / EBITDA -2.96 x - -0.87 x 0.34 x -0.77 x
EV / FCF - - -0.81 x 0.33 x -0.75 x
FCF Yield - - -124% 303% -133%
Price to Book - - 2.93 x 0.76 x -
Nbr of stocks (in thousands) 16,100 35,939 35,939 - -
Reference price 2 3.800 1.735 0.9680 0.9680 0.9680
Announcement Date 2/22/22 2/21/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2023 2024 2025 2026
Net sales 0.002 - - - - -
EBITDA 1 - -20.69 - -25 -36 -44
EBIT 1 - -20.69 - -25 -36 -44
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 - - - -27 -37 -45
Net income 1 -6.019 - -17.9 -27 -37 -45
Net margin -300,950% - - - - -
EPS 2 - - -1.010 -0.7500 -1.040 -1.260
Free Cash Flow 1 - - - -27 -37 -45
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/14/21 2/22/22 2/21/24 - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2023 2024 2025 2026
Net Debt 1 - - - - - -
Net Cash position 1 - - - 13 47 1
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 - - - -27 -37 -45
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share 2 - - - 0.3300 1.270 -
Cash Flow per Share - - - - - -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 4/14/21 2/22/22 2/21/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODUS THERAPEUTICS HOLDING AB Stock Modus Therapeutics Holding AB
-44.21% 3.17M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MODTX Stock
  4. Financials Modus Therapeutics Holding AB